Press Releases

 
Press Releases
  Date Title and Summary View
May 6, 2016
AMES, Iowa, May 06, 2016 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of discovering, developing and commercializing novel immuno-oncology product candidates, including both cellular immunotherapy and checkpoint inhibitor programs, to improve the lives of patients with cancer, today ...
Apr 29, 2016
IMPRESS Phase 3 Top-line Results Now Expected in Second Quarter of 2016Pancreatic and Melanoma IDO Pathway Inhibitor Trial Updates at ASCO -Management to Host Conference Call Today at 8:30 a.m. ET AMES, Iowa and AUSTIN, Texas, April 29, 2016 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the f...
Apr 25, 2016
AMES, Iowa, April 25, 2016 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of discovering, developing and commercializing novel immuno-oncology and infectious disease product candidates, announced today that the Biomedical Advanced Research and Development Authority (BARDA) of the Unite...
Apr 21, 2016
AMES, Iowa, April 21, 2016 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of discovering, developing and commercializing novel immuno-oncology product candidates, including both cellular immunotherapy and checkpoint inhibitor programs, to improve the lives of patients with cancer, toda...
Apr 15, 2016
AMES, Iowa, April 15, 2016 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of discovering, developing and commercializing novel immuno-oncology and infectious disease product candidates, announced today that the Defense Threat Reduction Agency (DTRA) of the United States Department of D...
Apr 6, 2016
AMES, Iowa, April 06, 2016 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of discovering, developing and commercializing novel immuno-oncology product candidates, including both cellular immunotherapy and checkpoint inhibitor programs, to improve the lives of patients with cancer, toda...
Feb 29, 2016
NewLink Genetics Outlines 2016 Business Priorities to Support Development of Immuno-Oncology Product Pipeline Management to Host Conference Call and Webcast Today at 8:30 a.m. ET AMES, Iowa, Feb. 29, 2016 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of discovering, developing a...
Feb 16, 2016
AMES, Iowa, Feb. 16, 2016 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer, announced today that it will participate in three upcoming investor conferences: Februa...
Feb 12, 2016
AMES, Iowa, Feb. 12, 2016 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of discovering, developing and commercializing novel immuno-oncology product candidates, including both cellular immunotherapy and checkpoint inhibitor platforms, will release its fourth quarter and year end 2015 ...
Feb 2, 2016
AMES, Iowa, Feb. 02, 2016 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of discovering, developing and commercializing novel immuno-oncology product candidates, including both cellular immunotherapy and checkpoint inhibitor platforms, today announced the company initiated a project to...
Page: FirstPrevious
3
... NextLast
= add release to Briefcase